Sign In
Buy ZVRA
$13.00
+0.350 (+2.77%)
At Close: Jun 23, 2026
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
07:38pm, Monday, 09'th Mar 2026
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
07:30am, Monday, 02'nd Mar 2026
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living wit
Zevra Therapeutics to Present at the Citizens Life Sciences Conference
07:30am, Wednesday, 25'th Feb 2026
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer
03:42pm, Tuesday, 24'th Feb 2026
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseas
San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigatio
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Short Interest Update
01:40am, Thursday, 19'th Feb 2026
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 4,7
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
01:51pm, Wednesday, 18'th Feb 2026
SAN DIEGO--(BUSINESS WIRE)---- $ZVRA #Zevra--Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevr
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients Real-world and clinical trial data underscore long-term safety and effectiveness in
Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
07:30am, Monday, 02'nd Feb 2026
CELEBRATION, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Receives Consensus Rating of “Moderate Buy” from Analysts
03:08am, Saturday, 31'st Jan 2026
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) has been given an average recommendation of "Moderate Buy" by the eight analysts that are currently covering the stock, MarketBeat Ratings rep
Zevra Therapeutics to Present Multiple Analyses on MIPLYFFA® at the 22nd Annual WORLDSymposium™
07:30am, Monday, 26'th Jan 2026
Four abstracts highlighting clinical data and real-world experience with MIPLYFFA accepted for presentation, including an oral presentation by Caroline Hastings, MD
Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:26pm, Thursday, 15'th Jan 2026
Zevra Therapeutics, Inc. (ZVRA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Zevra Therapeutics: Asymmetric Risk-Reward Setup In Ultra-Rare Disease Market
07:26am, Saturday, 03'rd Jan 2026
Zevra Therapeutics reported Q3 FY25 revenues of $26.1M, up 605% YoY, driven by MIPLYFFA, and is nearing profitability. ZVRA's valuation appears deeply discounted, with significant upside from EU expan
Financial Review: Zevra Therapeutics (NASDAQ:ZVRA) versus Journey Medical (NASDAQ:DERM)
01:27am, Friday, 26'th Dec 2025
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Journey Medical (NASDAQ: DERM - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the t
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 12'th Dec 2025
CELEBRATION, Fla., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with
